MYIA
FLNA

Mount Yale Investment Advisors’s Filana Therapeutics FLNA Stock Holding History

Mount Yale Investment Advisors’s Portfolio FLNA Stock Details FLNA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q3 		– Sell
-100
Closed -$181 – 1429
2025
Q2 		$181 Buy
+100
New +$178 ﹤0.01% 1459

Other funds holding FLNA

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Marshall Wace
Marshall Wace London, United Kingdom $100B AUM 35.1% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Two Sigma Advisers
Two Sigma Advisers New York $51.4B AUM 31.07% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return
GC
GMT Capital Atlanta, Georgia $2.19B AUM 72.3% 1-Year Est. Return
6CM
683 Capital Management New York $1.92B AUM 85.52% 1-Year Est. Return

Mount Yale Investment Advisors's FLNA Position: Q3 2025 in Review

Mount Yale Investment Advisors sold out of Filana Therapeutics (FLNA) in Q3 2025, closing a stake of 100 shares — an estimated $181 sold.

Mount Yale Investment Advisors first reported a position in FLNA in Q2 2025 and held it in 1 quarter. The position peaked at $181 in Q2 2025. 103 funds tracked by Wall St. Rank hold FLNA as of Q3 2025.

  • Mount Yale Investment Advisors reported no remaining Filana Therapeutics position as of Q3 2025 after selling out during the quarter.
  • Mount Yale Investment Advisors sold 100 Filana Therapeutics shares in Q3 2025, an estimated $181.
  • Mount Yale Investment Advisors first reported a position in Filana Therapeutics in Q2 2025 and held it in 1 quarter.
  • Mount Yale Investment Advisors's Filana Therapeutics position peaked at $181 in Q2 2025.
  • 103 funds tracked by Wall St. Rank held Filana Therapeutics as of Q3 2025.

Based on Mount Yale Investment Advisors's 13F filing for Q3 2025, filed 14 Nov 2025.